We remain largely without effective prophylactic/therapeutic interventions for COVID-19. Although many human COVID-19 clinical trials are ongoing, there remains a deficiency of supportive preclinical drug efficacy studies to help guide decisions. Here we assessed the prophylactic/therapeutic efficacy of hydroxychloroquine (HCQ), a drug of interest for COVID-19 management, in 2 animal disease models. The standard human malaria HCQ prophylaxis (6.5 mg/kg given weekly) and treatment (6.5 mg/kg given daily) did not significantly benefit clinical outcome, nor did it reduce SARS-CoV-2 replication/shedding in the upper and lower respiratory tract in the rhesus macaque disease model. Similarly, when used for prophylaxis or treatment, neither the standard human malaria dose (6.5 mg/kg) nor a high dose (50 mg/kg) of HCQ had any beneficial effect on clinical disease or SARS-CoV-2 kinetics (replication/shedding) in the Syrian hamster disease model. Results from these 2 preclinical animal models may prove helpful in guiding clinical use of HCQ for prophylaxis/treatment of COVID-19. The use of hydroxychloroquine was assessed as a possible therapeutic in two COVID-19 animal models and was found to be ineffective.
【저자키워드】 COVID-19, Cytokines, Molecular biology, Therapeutics, Drug screens, 【초록키워드】 Treatment, SARS-CoV-2, Efficacy, High dose, clinical trial, Hydroxychloroquine, Intervention, animal model, drug, Clinical outcome, Prophylaxis, malaria, management, therapeutic, HCQ, respiratory, disease, rhesus macaque, dose, Lower respiratory tract, deficiency, Clinical use, Drug efficacy, disease models, help, upper and lower respiratory tract, clinical disease, rhesus, effective, benefit, Result, significantly, reduce, use of hydroxychloroquine, 【제목키워드】 Treatment, Hydroxychloroquine, SARS-CoV-2 disease,